"10.1371_journal.pone.0061494","plos one","2013-04-19T00:00:00Z","Saskia Woudstra; Marie-José van Tol; Zoltán Bochdanovits; Nic J van der Wee; Frans G Zitman; Mark A van Buchem; Esther M Opmeer; André Aleman; Brenda W Penninx; Dick J Veltman; Witte J Hoogendijk","Department of Psychiatry, VU University Medical Center, Amsterdam, The Netherlands; Department of Medical Genomics, VU University Medical Center, Amsterdam, The Netherlands; Department of Psychiatry, Leiden University Medical Center, Leiden, The Netherlands; Leiden Institute for Brain and Cognition, Leiden University, Leiden, The Netherlands; Neuroscience Campus Amsterdam, VU University, Amsterdam, The Netherlands; NeuroImaging Center & Department of Neuroscience, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands; Department of Behavioral Neurology, Leibniz Institute for Neurobiology, Magdeburg, Germany; Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands; Department of Psychology, Groningen University, Groningen, The Netherlands; Department of Psychiatry, Erasmus Medical Center, Rotterdam, The Netherlands","Interpretation of data and critical revision of the manuscript: ZB NJvdW FGZ MAvB EMO AA BWP DJV WJH. Conceived and designed the experiments: NJvdW FGZ MAvB AA BWP DJV WJH. Performed the experiments: SW MJvT DJV. Analyzed the data: SW MJvT ZB DJV. Wrote the paper: SW MJvT DJV.","N.J.A. van der Wee received speaking fees from Eli Lilly and Wyeth and served on advisory panels of Eli Lilly, Pfizer, Wyeth, and Servier. A. Aleman received an investigator-initiated unrestricted research grant from Brystol-Myers Squibb and speakers bureau honoraria from AstraZeneca, Brystol-Myers Squibb, and GlaxoSmithKline. W.J. Hoogendijk lectured and advised for, and received unrestricted research grants from, Eli Lilly, Lundbeck, Servier, Bristol-Myers Squibb, and Organon for which payments were made to the independent research foundation of GGZ inGeest. W.J. Hoogendijk holds the following patent for gene-expression profiling in peripheral blood as a biomarker for depression (Name: Means and methods for typing a cell isolate of an individual suffering from a psychiatric disorder or at risk of suffering there from; Number: PCT/NL2008/050837; Date: December 19, 2008 [19.12.2008]).There are no further patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2013","04","Saskia Woudstra","SW",11,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA
